Approved indications: In adults, Caplyta is approved to treat schizophrenia, depressive episodes associated with bipolar I or II disorder (bipolar depression) either alone or with lithium/valproate, and as add-on therapy to antidepressants for major depressive disorder (MDD).

Off-label uses: There are no widely established off-label uses; research is ongoing for other mood and psychiatric conditions, but routine prescribing outside the approved indications is limited and should be based on specialist judgment and emerging evidence.

Efficacy expectations: Some people notice sleep and anxiety improvements within 1 to 2 weeks, with fuller effects on mood and psychotic symptoms often taking 4 to 6 weeks or longer; in trials, Caplyta reduced depressive and psychotic symptoms more than placebo, with efficacy generally comparable to other second-generation antipsychotics but with relatively low rates of weight gain, metabolic changes, and movement disorders, while sedation and dizziness remain common.

Typical dosing and how to take it: For adults with schizophrenia, bipolar depression, or as adjunctive therapy for MDD, the recommended dose is 42 mg orally once daily, taken at about the same time each day, with or without food; many people prefer taking it in the evening to lessen daytime sedation. Swallow the capsule whole with water and do not crush, chew, or open it.

Special dosing instructions: No dose titration is needed when starting Caplyta. A reduced dose of 21 mg once daily is recommended in adults with moderate or severe hepatic (liver) impairment. When used with strong CYP3A4 inhibitors (such as certain antifungals or some antibiotics), the recommended dose is 10.5 mg once daily, and with moderate CYP3A4 inhibitors it is 21 mg once daily. Concomitant use with CYP3A4 inducers (such as rifampin, carbamazepine, or St. John’s wort) should generally be avoided because they may make the medicine less effective.

Missed dose: If you miss a dose, take it as soon as you remember on the same day unless it is almost time for your next dose, in which case skip the missed dose and resume your regular schedule; do not take two doses at once to make up for a missed dose.

Overdose: In case of overdose or if someone has taken more than prescribed, seek emergency medical care or contact a poison control center right away, as severe drowsiness, agitation, abnormal movements, very low blood pressure, or heart rhythm changes can occur.

Common side effects: The most frequent reactions include somnolence/sedation, dizziness, dry mouth, nausea, fatigue, and sometimes diarrhea; these usually begin in the first days to weeks of treatment, are often mild to moderate, and may improve as your body adjusts, but can increase the risk of falls or accidents.

Serious or rare adverse effects: Seek urgent medical attention for signs of neuroleptic malignant syndrome (high fever, stiff muscles, confusion, fast heartbeat), severe stiffness or uncontrollable movements, rash or swelling suggesting an allergic reaction, seizures, thoughts of self-harm, or sudden worsening of mood or behavior; like other antipsychotics, Caplyta carries a boxed warning for increased death in older adults with dementia-related psychosis and is not approved for that use, and for increased risk of suicidal thoughts and behavior when used with antidepressants in younger patients.

Warnings and precautions: Use cautiously in people with a history of seizures, low white blood cell counts, heart disease, low blood pressure, or who are at risk of falls; it may cause orthostatic hypotension (blood pressure drops when standing), so getting up slowly is advised. In pregnancy, third-trimester exposure to antipsychotics may cause withdrawal or movement symptoms in newborns, so risks and benefits must be carefully weighed. It is not known if lumateperone passes into breast milk; clinicians may recommend avoiding breastfeeding or monitoring the infant for sedation and feeding problems. Safety and effectiveness have not been established in children or adolescents.

Safety compared with similar drugs: Compared with many other second-generation antipsychotics, Caplyta tends to cause less weight gain, cholesterol and blood sugar changes, and fewer extrapyramidal (Parkinson-like) symptoms, but it can be more sedating for some people, and it still shares class risks such as tardive dyskinesia, neuroleptic malignant syndrome, and metabolic changes.

Side-effect reporting and safety updates: Side effects should be reported to your prescriber and can also be reported to the FDA’s MedWatch program (1-800-FDA-1088) or to the drug manufacturer; updated safety information is posted in the Medication Guide and on FDA safety communications for Caplyta.

Drug and supplement interactions: Caplyta is metabolized mainly by CYP3A4, so strong or moderate CYP3A4 inhibitors (for example, some antifungals, macrolide antibiotics, HIV protease inhibitors, and certain other drugs) can raise its levels and require dose reduction, while CYP3A4 inducers (such as rifampin, carbamazepine, phenytoin, or St. John’s wort) can lower its levels and should generally be avoided. Combining Caplyta with other medicines that cause drowsiness (benzodiazepines, opioids, sedating antihistamines, alcohol) can increase sedation and risk of falls. Caution is also advised with other drugs that affect heart rhythm (QT-prolonging agents) or lower blood pressure.

Food, alcohol, and other products: Caplyta can be taken with or without meals, but grapefruit and grapefruit juice may increase drug levels and are usually avoided. Alcohol can markedly increase drowsiness and impair judgment or coordination, so limiting or avoiding alcohol while taking Caplyta is recommended.

Conditions requiring extra caution: Use with caution or dose adjustment in people with moderate to severe liver impairment, a history of seizures, heart disease, low blood pressure, low white blood cell counts, or metabolic risk factors (diabetes, obesity, dyslipidemia). It is not approved for use in older adults with dementia-related psychosis due to increased risk of death, and it is not established for children or adolescents.

Monitoring needs: Clinicians may periodically monitor weight, waist circumference, blood pressure, fasting blood glucose, and lipid levels, as with other antipsychotics, and may check complete blood counts or movement exams if symptoms arise. Mental status, suicidality (especially when used with antidepressants), and emergence of abnormal movements should be routinely assessed.

Q: How long does it take for Caplyta to start working?
A: Some people notice better sleep or reduced anxiety within 1 to 2 weeks, but improvements in mood and psychotic symptoms often continue to build over 4 to 6 weeks or longer, so it is important to keep taking it as prescribed unless your clinician advises otherwise.

Q: Will Caplyta make me gain weight?
A: Caplyta can cause some weight gain, but on average it tends to have a lower impact on weight, cholesterol, and blood sugar than many other atypical antipsychotics, though your weight and labs should still be monitored over time.

Q: When is the best time of day to take Caplyta?
A: You can take it at any time of day, with or without food, but because it often causes drowsiness, many people and clinicians prefer taking it in the evening or at bedtime if tolerated.

Q: Can I drink alcohol while taking Caplyta?
A: Alcohol can increase drowsiness, dizziness, and judgment problems caused by Caplyta, so it is generally best to avoid or minimize alcohol and to discuss any use with your prescriber.

Q: Is Caplyta safe during pregnancy or breastfeeding?
A: Data in pregnancy and breastfeeding are limited; as with other antipsychotics, late-pregnancy exposure can cause withdrawal or movement symptoms in newborns, and because it is unknown how much enters breast milk, decisions about continuing Caplyta and whether to breastfeed should be made with your clinician, weighing the benefits of treatment against potential risks.

Storage: Store Caplyta capsules at room temperature (generally 68°F to 77°F / 20°C to 25°C), in the original tightly closed container, protected from excess moisture and heat, and out of reach of children and pets.

Disposal: Do not keep unused or expired capsules; if a drug take-back program or authorized collection site is available, use it, and if not, mix capsules (without crushing them) with an undesirable substance such as used coffee grounds or cat litter, seal in a bag or container, place in household trash, and remove or black out personal information on the prescription label.